Understanding Molecular Response with Respect to Cure for CML
Dr. Neil Shah relates the management of CML, for most chronic phase patients, to the management of high blood pressure; while patients should remain diligent and serious about their treatment, they can expect to live long and healthy lives. Dr. Shah explains that this level of disease management has led researchers to begin looking for answers to more sophisticated questions. One such research question hopes to refine the expectations CML physicians and patients should have regarding complete and major molecular responses, and for whom treatment interruption may be a viable option.
Experts & Guests
Neil Shah, M.D., Ph.D.
Co-Leader of the Hematologic Malignancies Program, UCSF Helen Diller Family Comprehensive Cancer CenterDr. Neil Shah is Co-Leader of the Hematologic Malignancies Program at UCSF Helen Diller Family Comprehensive Cancer Center and Assistant Professor in Division of Hematology/Oncology at the UCSF School of Medicine. Dr. Shah completed his medical degree and PhD in Microbiology and Molecular Genetics at the University of California, Los Angeles. more >